HCWB (HCW Biologics) Operating Margin %: 49.67% (As of Mar. 2026)


HCWB HCW Biologics Inc HCWB
39 GF Score
Price $1.15
GF Value $7.29
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is HCW Biologics Operating Margin %?

HCW Biologics HCWB +4.09% 39 Operating Margin % is 49.67% as of Mar. 2026. GuruFocus rates HCWB with a GF Score™ of 39/100 and a GF Value™ of $7.29 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 945 Biotechnology companies, HCW Biologics ranks worse than 51.22% on this metric.

Operating Margin % is calculated as Operating Income divided by its Revenue. HCW Biologics's Operating Income for the three months ended in Mar. 2026 was $3.25 Mil. HCW Biologics's Revenue for the three months ended in Mar. 2026 was $6.54 Mil. Therefore, HCW Biologics's Operating Margin % for the quarter that ended in Mar. 2026 was 49.67%.

The historical rank and industry rank for HCW Biologics's Operating Margin % or its related term are showing as below:

HCWB' s Operating Margin % Range Over the Past 10 Years
Min: -20846.3   Med: -904.89   Max: -96.1
Current: -96.1


HCWB's Operating Margin % is ranked worse than
51.22% of 945 companies
in the Biotechnology industry
Industry Median: -86.89 vs HCWB: -96.10

HCW Biologics's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

HCW Biologics's Operating Income for the three months ended in Mar. 2026 was $3.25 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 was $-6.34 Mil.

Warning Sign:

HCW Biologics Inc had lost money in 92% of the time over the past 12quarters.


HCW Biologics  (NAS:HCWB) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


HCW Biologics Operating Margin % Related Terms


HCW Biologics Operating Margin % Historical Data

* Premium members only.

The historical data trend for HCW Biologics's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

HCW Biologics Operating Margin % Chart

HCW Biologics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Operating Margin %
Get a 7-Day Free Trial 0.00 -224.32 -904.89 -1,076.31 -20,846.30

HCW Biologics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -33,860.00 -48,028.57 -20,481.25 -10,914.81 49.67

HCWB vs MTVA, INTI, HOOK: Operating Margin % Comparison

For the Biotechnology subindustry, HCW Biologics's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HCW Biologics Operating Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, HCW Biologics's Operating Margin % distribution charts can be found below:

* The bar in red indicates where HCW Biologics's Operating Margin % falls into.


HCWB
39GF Score
HCW Biologics Inc HCWB
Operating Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

HCW Biologics Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

HCW Biologics's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as

Operating Margin %=Operating Income (A: Dec. 2025 ) / Revenue (A: Dec. 2025 )
=-11.257 / 0.054
=-20,846.30 %

HCW Biologics's Operating Margin % for the quarter that ended in Mar. 2026 is calculated as

Operating Margin %=Operating Income (Q: Mar. 2026 ) / Revenue (Q: Mar. 2026 )
=3.25 / 6.543
=49.67 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Margin % →
What does a Operating Margin % of 49.67% mean?
HCW Biologics (HCWB) has a Operating Margin % of 49.67% as of Mar. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on HCW Biologics and its competitors. According to the industry distribution chart, HCW Biologics ranks #484 out of 945 companies in the Biotechnology industry, placing it in the top 51.2%.
Is HCW Biologics' Operating Margin % too high?
HCW Biologics' current Operating Margin % is 49.67%. Based on the distribution chart, HCW Biologics ranks #484 out of 945 companies in the Biotechnology industry, which is below the industry midpoint. Overall, HCW Biologics has a GF Score™ of 39/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does HCW Biologics' Operating Margin % compare to MTVA and INTI?
According to the Biotechnology industry distribution chart, HCW Biologics ranks #484 out of 945 companies for Operating Margin %. This places HCW Biologics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on HCW Biologics and its competitors. HCW Biologics's current Operating Margin % is 49.67%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HCW Biologics stock overvalued right now?
Based on GuruFocus' analysis, HCW Biologics (HCWB) is currently considered Possible Value Trap. The stock's GF Value™ is $7.29, compared to a current price of $1.15 — trading 84.3% below its estimated fair value. The current Operating Margin % is 49.67%. HCW Biologics' overall GF Score™ is 39/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For HCW Biologics (HCWB), the current Operating Margin % is 49.67% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is HCW Biologics (HCWB) Overvalued in 2026?

Based on GuruFocus' analysis, HCW Biologics stock appears to be undervalued. The current stock price of $1.15 is trading 84.3% below its estimated GF Value™ of $7.29. GuruFocus considers HCW Biologics to be Possible Value Trap.

Key valuation signals for HCWB:

  • Operating Margin %: 49.67%
  • GF Value™: $7.29 vs. price of $1.15 (84.3% below fair value)
  • GF Score™: 39/100 with 7 warning signs

No single metric tells the full story. See the HCWB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


HCW Biologics Business Description

Address 2929 N. Commerce Parkway, Miramar, FL, USA, 33025
HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.
39GF Score

Get the complete analysis for HCWB

Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.15
Price
$7.29
GF Value